These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33567158)

  • 1. Measuring financial toxicity in Australian cancer patients - Validation of the COmprehensive Score for financial Toxicity (FACT COST) measuring financial toxicity in Australian cancer patients.
    Durber K; Halkett GK; McMullen M; Nowak AK
    Asia Pac J Clin Oncol; 2021 Aug; 17(4):377-387. PubMed ID: 33567158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial toxicity in patients with cancer attending a public Australian tertiary hospital: A pilot study.
    McLean L; Hong W; McLachlan SA
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):245-252. PubMed ID: 32894819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
    de Souza JA; Yap BJ; Wroblewski K; Blinder V; Araújo FS; Hlubocky FJ; Nicholas LH; O'Connor JM; Brockstein B; Ratain MJ; Daugherty CK; Cella D
    Cancer; 2017 Feb; 123(3):476-484. PubMed ID: 27716900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity, test-retest reliability, and responsiveness of the Indonesian version of FACIT-COST measure for subjective financial toxicity.
    Pangestu S; Purba FD; Setyowibowo H; Mukuria C; Rencz F
    Health Qual Life Outcomes; 2024 Oct; 22(1):89. PubMed ID: 39427212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation and validation of the Traditional Chinese version of the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (Version 2).
    Chan DNS; Choi KC; Ng MSN; Xing W; Law BMH; Ho PS; Au C; Chan M; Tong M; Ling WM; Chan M; Mak SSS; Chan RJ; So WKW
    Health Qual Life Outcomes; 2021 Jan; 19(1):17. PubMed ID: 33419447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors.
    Shim S; Kang D; Kim N; Han G; Lim J; Kim H; Park J; Lee M; Lee JE; Kim SW; Yu J; Chae BJ; Ryu JM; Nam SJ; Lee SK; Cho J
    Cancer Res Treat; 2022 Jul; 54(3):834-841. PubMed ID: 34645130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of FinTox: A new screening tool to assess cancer-related financial toxicity.
    Badr H; Han J; Mims M
    Cancer Med; 2024 Aug; 13(15):e7306. PubMed ID: 39113222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COmprehensive Score for financial Toxicity in China: Validation and Responsiveness.
    Yu HH; Yu ZF; Li H; Zhao H; Sun JM; Liu YY
    J Pain Symptom Manage; 2021 Jun; 61(6):1297-1304.e1. PubMed ID: 33412268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement and Validation of the Comprehensive Score for Financial Toxicity (COST) in a Population With Diabetes.
    Patel MR; Zhang G; Heisler M; Song PXK; Piette JD; Shi X; Choe HM; Smith A; Resnicow K
    Diabetes Care; 2022 Nov; 45(11):2535-2543. PubMed ID: 36048837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability and validity of the adapted Dutch version of the revised Scoliosis Research Society 22-item questionnaire.
    Schlösser TP; Stadhouder A; Schimmel JJ; Lehr AM; van der Heijden GJ; Castelein RM
    Spine J; 2014 Aug; 14(8):1663-72. PubMed ID: 24360746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two validated instruments to measure financial hardship in cancer survivors: comprehensive score for financial toxicity (COST) versus personal financial wellness (PFW) scale.
    D'Rummo KA; Nganga D; Chollet-Hinton L; Shen X
    Support Care Cancer; 2022 Dec; 31(1):12. PubMed ID: 36513902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Financial Toxicity of Radiation Oncology Patients Using the Validated Comprehensive Score for Financial Toxicity as a Patient-Reported Outcome.
    D'Rummo KA; Miller L; TenNapel MJ; Shen X
    Pract Radiat Oncol; 2020; 10(5):e322-e329. PubMed ID: 31634632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Prevalence of Financial Toxicity, its Predictors and Association with Health- Related Quality of Life Among Radiation Oncology Patients in India: A Cross-Sectional Patient Reported Outcome Study.
    Dar MA; Chauhan R; Trivedi V; Kumar R; Dhingra S
    Int J Radiat Oncol Biol Phys; 2023 May; 116(1):157-165. PubMed ID: 36455689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the COmprehensive Score for Financial Toxicity (COST) in Vietnamese patients with cancer.
    Tran BT; Le DD; Nguyen TG; Nguyen MT; Nguyen MH; Dang CK; Tran DT
    PLoS One; 2024; 19(6):e0306339. PubMed ID: 38941304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system.
    Parker C; Ayton D; Zomer E; Liew D; Vassili C; Fong CY; Wei A
    Leuk Res; 2022 Jan; 112():106748. PubMed ID: 34798569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire.
    Hueniken K; Douglas CM; Jethwa AR; Mirshams M; Eng L; Hope A; Chepeha DB; Goldstein DP; Ringash J; Hansen A; Martino R; Li M; Liu G; Xu W; de Almeida JR
    Cancer; 2020 Sep; 126(17):4042-4050. PubMed ID: 32603521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer.
    Kajimoto Y; Shibutani T; Nagao S; Yamaguchi S; Suzuki S; Mori M; Tsubouchi H; Nakao K; Azuma A; Koyanagi T; Kohara I; Tamaki S; Yabuki M; Teng L; Honda K; Igarashi A
    Int J Gynecol Cancer; 2022 Apr; ():. PubMed ID: 35444012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Economic Impact on Australian Patients with Neuroendocrine Tumours.
    Gordon LG; Elliott TM; Wakelin K; Leyden S; Leyden J; Michael M; Pavlakis N; Mumford J; Segelov E; Wyld DK
    Patient; 2020 Jun; 13(3):363-373. PubMed ID: 32072460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity and reliability of the Italian version of the ECOS-16 questionnaire in postmenopausal women with prevalent vertebral fractures due to osteoporosis.
    Salaffi F; Malavolta N; Cimmino MA; Di Matteo L; Scendoni P; Carotti M; Stancati A; Mulé R; Frigato M; Gutierrez M; Grassi W;
    Clin Exp Rheumatol; 2007; 25(3):390-403. PubMed ID: 17631735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial Toxicity in Crohn's Disease.
    Voit A; Cross RK; Bellavance E; Bafford AC
    J Clin Gastroenterol; 2019; 53(10):e438-e443. PubMed ID: 30358642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.